Supplementary Data S2 from On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models

Savel, Hélène; Barbier, Sandrine; Proust-Lima, Cécile; Rondeau, Virginie; Thiébaut, Rodolphe; Meyer-Losic, Florence; Richert, Laura

doi:10.1158/2767-9764.22545896.v1

sorry, we can't preview this file

crc-22-0238-s02.docx (19.45 kB)

Supplementary Data S2 from On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models

journal contribution

posted on 2023-04-04, 02:00 authored by Hélène Savel, Sandrine Barbier, Cécile Proust-Lima, Virginie Rondeau, Rodolphe Thiébaut, Florence Meyer-Losic, Laura Richert

Details on statistical modeling strategy.

Funding

Ipsen (Ipsen S.A.)

History

ARTICLE ABSTRACT

This work brings new arguments to a controversy on the correct choice of statistical modeling methods for the analysis of MCTs. We conclude that mixed models are more robust than joint models.

Usage metrics

Keywords

Biostatistics Preclinical Models Animal models of cancer Xenograft models Translational Research

Licence

CC BY

sorry, we can't preview this file

Supplementary Data S2 from On the Choice of Longitudinal Models for the Analysis of Antitumor Efficacy in Mouse Clinical Trials of Patient-derived Xenograft Models

Funding

Ipsen (Ipsen S.A.)

History

ARTICLE ABSTRACT

Usage metrics

Categories

Keywords

Licence

Exports